At 50 mg/kg, resveratrol (RES) substantially reduced lung tissue destruction in a dual-hit COPD mouse model (LPS instillation plus cigarette smoke), lowering mean linear intercept, destructive index, bronchoalveolar lavage inflammatory cell counts, and cytokine levels including IL-6 and TNF-α. Mechanistically, RES suppressed macrophage M1 polarization by downregulating TLR4, phospho-p65, and hexokinase 2 (HK2), reducing glucose uptake, lactate production, and extracellular acidification rate (ECAR) while recovering oxygen consumption rate (OCR). TLR4 overexpression reversed these gains; HK2 silencing partially restored them, confirming a TLR4→HK2 glycolytic axis as the operative mechanism.
This work sits at a productive intersection of immunometabolism and respiratory disease. The Warburg-like metabolic shift in pro-inflammatory macrophages — where HK2-driven glycolysis fuels cytokine output — has emerged as a tractable drug target across multiple chronic inflammatory diseases, but COPD-specific mechanistic evidence has lagged. Placing resveratrol upstream of HK2 via TLR4/NF-κB adds precision to what has historically been a diffuse polyphenol story. That said, critical limitations apply: the mouse model does not recapitulate the years-long pathology of human COPD, RAW264.7 cells are an immortalized line rather than primary human alveolar macrophages, and resveratrol's notoriously poor oral bioavailability in humans is unaddressed at this dose. Overall, this is a mechanistically disciplined incremental advance — useful for target validation but well short of translational readiness.